Shanghai CP Guojian Pharmaceutical Co., Ltd.

Quick facts

Phase 3 pipeline

• CHOP, CMAB304 · Oncology
  CMAB304 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity.
• CHOP combined with CMAB304 · Oncology
  CHOP chemotherapy combined with CMAB304 (a monoclonal antibody) targets cancer cells through cytotoxic chemotherapy while enhancing immune response through antibody-mediated mechanisms.

Phase 2 pipeline

• humanized anti-HER2 antibody

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Shanghai CP Guojian Pharmaceutical Co., Ltd. portfolio CI brief
• Shanghai CP Guojian Pharmaceutical Co., Ltd. pipeline updates RSS